Métastases non résécables des cancers colorectaux Utilisation pratique des nouvelles molécules (anti-EGFR, anti-angiogéniques)

Mohamed Hebbar, Agne`s Wacrenier, Christophe Desauw, Olivier Romano, Ste??phane Cattan, Jean-Pierre Triboulet, Francois-Rene?? Pruvot, Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anti-Cancer Drugs. ,vol. 17, pp. 855- 857 ,(2006) , 10.1097/01.CAD.0000217425.44584.9F

F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685

Jane Pruemer, Treatment of cancer-associated thrombosis: distinguishing among antithrombotic agents. Seminars in Oncology. ,vol. 33, pp. 26- 39 ,(2006) , 10.1053/J.SEMINONCOL.2006.01.021

Frank A. Scappaticci, Louis Fehrenbacher, Thomas Cartwright, John D. Hainsworth, William Heim, Jordan Berlin, Fairooz Kabbinavar, William Novotny, Somnath Sarkar, Herbert Hurwitz, Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab Journal of Surgical Oncology. ,vol. 91, pp. 173- 180 ,(2005) , 10.1002/JSO.20301

Caroline Robert, Jean-Charles Soria, Alain Spatz, Axel Le Cesne, David Malka, Patricia Pautier, Janine Wechsler, Catherine Lhomme, Bernard Escudier, Valérie Boige, Jean-Pierre Armand, Thierry Le Chevalier, Cutaneous side-effects of kinase inhibitors and blocking antibodies Lancet Oncology. ,vol. 6, pp. 491- 500 ,(2005) , 10.1016/S1470-2045(05)70243-6

W. De Roock, H. Piessevaux, J. De Schutter, M. Janssens, G. De Hertogh, N. Personeni, B. Biesmans, J.-L. Van Laethem, M. Peeters, Y. Humblet, E. Van Cutsem, S. Tejpar, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Annals of Oncology. ,vol. 19, pp. 508- 515 ,(2008) , 10.1093/ANNONC/MDM496

M Frattini, P Saletti, E Romagnani, V Martin, F Molinari, M Ghisletta, A Camponovo, L L Etienne, F Cavalli, L Mazzucchelli, PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. British Journal of Cancer. ,vol. 97, pp. 1139- 1145 ,(2007) , 10.1038/SJ.BJC.6604009

Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, David D. Chang, Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 26, pp. 1626- 1634 ,(2008) , 10.1200/JCO.2007.14.7116

Alfredo Falcone, Sergio Ricci, Isa Brunetti, Elisabetta Pfanner, Giacomo Allegrini, Cecilia Barbara, Lucio Crinò, Giovanni Benedetti, Walter Evangelista, Laura Fanchini, Enrico Cortesi, Vincenzo Picone, Stefano Vitello, Silvana Chiara, Cristina Granetto, Gianfranco Porcile, Luisa Fioretto, Cinzia Orlandini, Michele Andreuccetti, Gianluca Masi, Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest Journal of Clinical Oncology. ,vol. 25, pp. 1670- 1676 ,(2007) , 10.1200/JCO.2006.09.0928

Fréderic Bibeau, Marie-Danièle Diebold, Philippe Rougier, Michel Ducreux, Gorana Tomasic, Jean-François Emile, Frédérique Penault-Llorca, Pierre Laurent-Puig, Astrid Lièvre, Jean-Baptiste Bachet, Valérie Boige, Anne Cayre, Delphine Le Corre, Emmanuel Buc, Marc Ychou, Olivier Bouché, Bruno Landi, Christophe Louvet, Thierry André, KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab Journal of Clinical Oncology. ,vol. 26, pp. 374- 379 ,(2008) , 10.1200/JCO.2007.12.5906